loading...| Preferred Name |
Olanzapine |
|
| Synonyms |
Zyprexa Zydis 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine LY 170053 OLANZAPINE Olanzapine Zyprexa olanzapine |
|
| Definitions |
A synthetic derivative of thienobenzodiazepine with antipsychotic, antinausea, and antiemetic activities. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotoninergic, dopaminergic, muscarinic M1-5, histamine H1, and alpha-1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. The antinausea and antiemetic effects of this agent appear to be due to the blockade of 5-HT2 and 5-HT3 receptors for serotonin. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through antagonism to dopamine D2 receptors with rapid ligand-receptor dissociation kinetics that help to minimize extrapyramidal symptoms (EPS). Olanzapine may also stimulate appetite. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47639 |
|
| ALT_DEFINITION |
A drug used to treat certain mental disorders. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of antipsychotic and a type of monoamine antagonist. |
|
| CAS_Registry |
132539-06-1 |
|
| CHEBI_ID |
CHEBI:7735 |
|
| Chemical_Formula |
C17H20N4S |
|
| code |
C47639 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 |
|
| Contributing_Source |
CTRP FDA HemOnc |
|
| DEFINITION |
A synthetic derivative of thienobenzodiazepine with antipsychotic, antinausea, and antiemetic activities. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotoninergic, dopaminergic, muscarinic M1-5, histamine H1, and alpha-1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. The antinausea and antiemetic effects of this agent appear to be due to the blockade of 5-HT2 and 5-HT3 receptors for serotonin. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through antagonism to dopamine D2 receptors with rapid ligand-receptor dissociation kinetics that help to minimize extrapyramidal symptoms (EPS). Olanzapine may also stimulate appetite. |
|
| Display_Name |
Olanzapine |
|
| FDA_UNII_Code |
N7U69T4SZR |
|
| FULL_SYN |
Zyprexa Zydis 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine LY 170053 OLANZAPINE Olanzapine Zyprexa olanzapine |
|
| label |
Olanzapine |
|
| Legacy Concept Name |
Olanzapine |
|
| NCI_Drug_Dictionary_ID |
449664 |
|
| PDQ_Closed_Trial_Search_ID |
449664 |
|
| PDQ_Open_Trial_Search_ID |
449664 |
|
| Preferred_Name |
Olanzapine |
|
| prefixIRI |
Thesaurus:C47639 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0171023 |
|
| subClassOf |